BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38479071)

  • 1. Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Zheng X; Yang R; Zhao Y; Zhang Y; Yuan G; Li W; Xiao Z; Dong X; Ma M; Guo Y; Wang W; Zhao X; Yang H; Qiu S; Peng Z; Liu A; Yu S; Zhang Y
    Virology; 2024 Jun; 594():110050. PubMed ID: 38479071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.
    Bai S; Kang Y; Chen W; Xie H; Zhang L; Lv M; Wang J; Wu J; Zhao W
    Viral Immunol; 2023 Oct; 36(8):526-533. PubMed ID: 37625037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern.
    Zhang RY; Yin XG; Zhou SH; Zhang HW; Lu J; He CB; Wang J; Wen Y; Li YT; Liu YL; Feng RR; Ding D; Wei HW; Gong R; Yang GF; Guo J
    Chem Commun (Camb); 2022 Mar; 58(24):3925-3928. PubMed ID: 35244125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
    Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
    Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants.
    Zhang Y; Zheng X; Sheng W; Liang H; Zhao Y; Zhu X; Yang R; Zhang Y; Dong X; Li W; Pei F; Ding L; Chang Z; Deng L; Yuan G; Yang Z; Zhu D; Yang X; Wang H
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
    Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
    Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.
    Gao F; Zheng M; Fan J; Ding Y; Liu X; Zhang M; Zhang X; Dong J; Zhou X; Luo J; Li X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186110. PubMed ID: 36882925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
    Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
    Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
    Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
    Buntinx E; Brochado L; Borja-Tabora C; Yu CY; Alberto ER; Montellano MEB; Carlos JC; Toloza LB; Hites M; Siber G; Clemens R; Ambrosino D; Qin H; Chen HL; Han HH; Hu B; Li P; Baccarini C; Smolenov I
    Vaccine; 2023 Mar; 41(11):1875-1884. PubMed ID: 36781334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.